研究单位：[1]Pfizer[2]C2 Research Center,Montgomery 4076784,Alabama 4829764,United States,36117[3]CENTER FOR DERMATOLOGY CLINICAL RESEARCH, Inc,Fremont 5350734,California 5332921,United States,94538[4]Rao Dermatology,Fresno 5350937,California 5332921,United States,93720[5]Cura Clinical Research,Oxnard 5380184,California 5332921,United States,93030[6]Southern California Clinical Research,Santa Ana 5392900,California 5332921,United States,92701[7]Dermatology of Boca,Boca Raton 4148411,Florida 4155751,United States,33431[8]Pediatric Skin Research,LLC,Coral Gables 4151871,Florida 4155751,United States,33146[9]Suncoast Skin Solutions,Jacksonville 4160021,Florida 4155751,United States,32256[10]University of Miami,Miami 4164138,Florida 4155751,United States,33136[11]Skin Research of South Florida LLC,Miami 4164138,Florida 4155751,United States,33173[12]Kindred Hair and Skin Center,Marriottsville 4361736,Maryland 4361885,United States,21104[13]Brigham & Women''s Hospital/Harvard Medical School,Boston 4930956,Massachusetts 6254926,United States,02115[14]Oakland Hills Dermatology,Auburn Hills 4984565,Michigan 5001836,United States,48326[15]Michigan Dermatology Institute,Waterford 5014130,Michigan 5001836,United States,48328[16]Twin Cities Dermatology Center,Minneapolis 5037649,Minnesota 5037779,United States,55416[17]Central Missouri Dermatology Research,Columbia 4381982,Missouri 4398678,United States,65201[18]Hickory Dermatology Research Center,Hickory 4470778,North Carolina 4482348,United States,28602[19]NW Dermatology Institute,Portland 5746545,Oregon 5744337,United States,97210[20]UPMC,Pittsburgh 5206379,Pennsylvania 6254927,United States,15213[21]Goodlettsville Dermatology Research,Goodlettsville 4625282,Tennessee 4662168,United States,37072[22]Epiphany Dermatology,Southlake 4733313,Texas 4736286,United States,76092[23]Raven Clinical Reseach,Fairfax 4758023,Virginia 6254928,United States,22033[24]Raven Clinical Reseach,McLean 4772354,Virginia 6254928,United States,22102[25]Frontier Dermatology,Mill Creek 5803457,Washington 5815135,United States,98012[26]Raven Clinical Reseach,Burlington 5247214,Wisconsin 5279468,United States,53105[27]Beijing Tongren Hospital,Beijing 1816670,China,100006[28]Peking University First Hospital,Beijing 1816670,China,100034[29]Peking University People''s Hospital,Beijing 1816670,China,100044[30]Dermatology Hospital of Southern Medical University,Guangzhou 1809858,China,510091[31]Huashan Hospital Affiliated to Fudan University,Shanghai 1796236,China,200040[32]Shanghai Skin Disease Hospital,Shanghai 1796236,China,200443[33]Ch Victor Dupouy,Argenteuil 3037044,France,95100[34]CHU de CAEN,Caen 3029241,France,14033[35]Rouen University Hospital,Rouen 2982652,France,76000[36]Hospital of the University of Occupational and Environmental Health,Kitakyushu-shi,Fukuoka 1863958,Japan,807-8556[37]Kurume University Hospital,Kurume-shi,Fukuoka 1863958,Japan,830-0011[38]Nagomi Dermatology Clinic,Ebina 6822128,Kanagawa 1860291,Japan,243-0432[39]Niigata University Medical & Dental Hospital,Niigata 1855431,Niigata 1855429,Japan,951-8520[40]Osaka Metropolitan University Hospital,Osaka 1853909,Osaka 1853904,Japan,545-0051[41]Hamamatsu University Hospital,Hamamatsu 1863289,Shizuoka 1851715,Japan,431-3192[42]Juntendo University Hospital,Bunkyo-ku,Tokyo 1850144,Japan,113-8431[43]Tokyo Medical University Hospital,Shinjuku-Ku,Tokyo 1850144,Japan,160-0023[44]Gloucestershire Hospitals NHS Foundation Trust,Gloucester 2648404,Gloucestershire,United Kingdom,GL13PX[45]Royal United Hospital Bath,Bath 2656173,United Kingdom,BA1 3NG[46]NHS Greater Glasgow and Clyde,Glasgow 2648579,United Kingdom,G4 0SF[47]Whipps Cross (Barts Health),London 2643743,United Kingdom,E11 1NR[48]London North West University Healthcare Trust,London 2643743,United Kingdom,NW10 7NS[49]Chelsea and Westminster NHS Foundation Trust,London 2643743,United Kingdom,SW10 9NH
研究目的：
Alopecia areata (AA) is a chronic relapsing autoimmune disease characterized by nonscarring hair loss affecting children, adolescents, and adults across all ages, races, and genders. AA primarily affects the scalp; however, it also can affect nails, eyelashes, eyebrows, and other hair follicles on the patient's body. The 3 main types of AA are: - Patchy alopecia (PA), as seen in 90% of clinical diagnoses - Alopecia totalis (AT), that affects all scalp hair - Alopecia universalis (AU), involving all scalp, face, and body hair Dermatologist preferences for utility and order of skin-directed therapies to treat AA vary widely, with treatment choices based on various factors such as patients' age, disease duration and severity (Meah et al., 2020). Ritlecitinib is a bioavailable small molecule that irreversibly binds to Janus kinase-3 (JAK3) and Tyrosine kinase Expressed in the hepatocellular Carcinoma kinase family (TEC). Ritlecitinib 50 mg once daily was approved by the FDA 23 June 2023 and EMA 20 July 2023 for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older. In Japan, ritlecitinib was approved on 26 June 2023 for the treatment of alopecia areata (limited to intractable cases involving widespread hair loss). Additional countries have since approved ritlecitinib. Those approvals are based on the results of the ritlecitinib pivotal phase 2b/3 study (ALLEGRO 2b/3) which examined efficacy and safety of ritlecitinib in AA patients globally. Despite positive results from the ALLEGRO program, there is still lack of evidence on ritlecitinib patients' characteristics and clinical outcomes in routine clinical practice. The investigators will evaluate patient and disease characteristics, treatment patterns, and clinical and patient-reported outcomes among patients with AA who are receiving ritlecitinib. The aim of this study is to measure effectiveness of ritlecitinib in a real-world setting. Ritlecitinib will be prescribed to patients according to the approved product label. Treatment will be guided by clinical judgement of the treating physician ie, study investigators, according to standard of care, independently of this study.
